187 related articles for article (PubMed ID: 23944364)
1. C-KIT signaling in cancer treatment.
Stankov K; Popovic S; Mikov M
Curr Pharm Des; 2014; 20(17):2849-80. PubMed ID: 23944364
[TBL] [Abstract][Full Text] [Related]
2. [The diagnostic and predictive role of kit (CD117)].
Dirnhofer S; Zimpfer A; Went P
Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
Masson K; Rönnstrand L
Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
[TBL] [Abstract][Full Text] [Related]
4. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
5. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
6. TAK1 and IKK2, novel mediators of SCF-induced signaling and potential targets for c-Kit-driven diseases.
Drube S; Weber F; Göpfert C; Loschinski R; Rothe M; Boelke F; Diamanti MA; Löhn T; Ruth J; Schütz D; Häfner N; Greten FR; Stumm R; Hartmann K; Krämer OH; Dudeck A; Kamradt T
Oncotarget; 2015 Oct; 6(30):28833-50. PubMed ID: 26353931
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
Kaitsiotou H; Keul M; Hardick J; Mühlenberg T; Ketzer J; Ehrt C; Krüll J; Medda F; Koch O; Giordanetto F; Bauer S; Rauh D
J Med Chem; 2017 Nov; 60(21):8801-8815. PubMed ID: 28991465
[TBL] [Abstract][Full Text] [Related]
8. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
9. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of c-KIT in cancer.
Ashman LK; Griffith R
Expert Opin Investig Drugs; 2013 Jan; 22(1):103-15. PubMed ID: 23127174
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.
Abbaspour Babaei M; Kamalidehghan B; Saleem M; Huri HZ; Ahmadipour F
Drug Des Devel Ther; 2016; 10():2443-59. PubMed ID: 27536065
[TBL] [Abstract][Full Text] [Related]
12. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
Smalley KS; Sondak VK; Weber JS
Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
[TBL] [Abstract][Full Text] [Related]
13. Role and significance of c-KIT receptor tyrosine kinase in cancer: A review.
Sheikh E; Tran T; Vranic S; Levy A; Bonfil RD
Bosn J Basic Med Sci; 2022 Sep; 22(5):683-698. PubMed ID: 35490363
[TBL] [Abstract][Full Text] [Related]
14. KIT as a therapeutic target for non-oncological diseases.
Martinez-Anton A; Gras D; Bourdin A; Dubreuil P; Chanez P
Pharmacol Ther; 2019 May; 197():11-37. PubMed ID: 30557630
[TBL] [Abstract][Full Text] [Related]
15. Targeting c-Kit mutations: basic science to novel therapies.
Sattler M; Salgia R
Leuk Res; 2004 May; 28 Suppl 1():S11-20. PubMed ID: 15036937
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells.
Fatrai S; van Schelven SJ; Ubink I; Govaert KM; Raats D; Koster J; Verheem A; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2015 Sep; 149(3):692-704. PubMed ID: 25962936
[TBL] [Abstract][Full Text] [Related]
17. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
[TBL] [Abstract][Full Text] [Related]
18. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors.
Pittoni P; Piconese S; Tripodo C; Colombo MP
Oncogene; 2011 Feb; 30(7):757-69. PubMed ID: 21057534
[TBL] [Abstract][Full Text] [Related]
19. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
20. The C-kit receptor-mediated signal transduction and tumor-related diseases.
Liang J; Wu YL; Chen BJ; Zhang W; Tanaka Y; Sugiyama H
Int J Biol Sci; 2013; 9(5):435-43. PubMed ID: 23678293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
